NASDAQ:OTIC - Otonomy Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 189.86 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.07
▼ -0.01 (-0.48%)

This chart shows the closing price for OTIC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Otonomy Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OTIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OTIC

Analyst Price Target is $6.00
▲ +189.86% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Otonomy in the last 3 months. The average price target is $6.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 189.86% upside from the last price of $2.07.

This chart shows the closing price for OTIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Otonomy. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2022OppenheimerBoost Price TargetOutperform$5.00 ➝ $6.00Medium
11/11/2021Cantor FitzgeraldReiterated RatingOverweightMedium
5/12/2021HC WainwrightReiterated RatingBuy$5.50Low
4/13/2021Piper SandlerBoost Price Target$5.00 ➝ $6.00High
2/23/2021HC WainwrightLower Price TargetBuy$10.00 ➝ $5.50Low
2/22/2021Piper SandlerLower Price Target$10.00 ➝ $5.00N/A
12/18/2020HC WainwrightBoost Price TargetPositive ➝ Buy$9.00 ➝ $10.00High
11/22/2020OppenheimerInitiated CoverageBuy$11.00Medium
8/17/2020Cantor FitzgeraldReiterated RatingOverweight$11.00High
8/6/2020HC WainwrightReiterated RatingBuy$9.00Low
7/7/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$9.00 ➝ $11.00High
7/7/2020HC WainwrightBoost Price TargetPositive ➝ Buy$8.00 ➝ $9.00High
7/6/2020OppenheimerReiterated RatingBuy$8.00High
6/16/2020HC WainwrightReiterated RatingBuy$8.00Low
6/16/2020Cantor FitzgeraldBoost Price TargetOverweight$3.00 ➝ $9.00High
6/5/2020HC WainwrightReiterated RatingBuy ➝ Market Perform$8.00Medium
5/29/2020OppenheimerInitiated CoverageBuy$8.00High
5/29/2020Craig HallumInitiated CoverageBuy$8.00High
12/24/2019OppenheimerInitiated CoverageOutperform$8.00High
11/6/2019HC WainwrightReiterated RatingBuy$8.00Medium
8/29/2019HC WainwrightInitiated CoverageBuy$8.00High
3/5/2019Piper Jaffray CompaniesReiterated RatingBuyLow
3/4/2019Cantor FitzgeraldReiterated RatingBuy$5.00High
11/14/2018Cantor FitzgeraldInitiated CoverageOverweight$9.00Medium
8/14/2018SunTrust BanksLower Price TargetBuy$10.00Low
3/19/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
3/12/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightMedium
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$8.00N/A
8/31/2017CowenReiterated RatingOutperform$55.00 ➝ $9.00Low
8/31/2017SunTrust BanksReiterated RatingBuy$45.00 ➝ $15.00High
8/30/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$32.00 ➝ $8.00High
8/30/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$28.00 ➝ $8.00High
8/23/2017CowenReiterated RatingOutperform$55.00Medium
8/15/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$28.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/6/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/5/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/4/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/5/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/5/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/4/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Otonomy logo
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.07
Low: $2.03
High: $2.10

50 Day Range

MA: $2.02
Low: $1.72
High: $2.51

52 Week Range

Now: $2.07
Low: $1.14
High: $2.59

Volume

1,523 shs

Average Volume

148,207 shs

Market Capitalization

$117.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Otonomy?

The following sell-side analysts have issued research reports on Otonomy in the last twelve months: Cantor Fitzgerald, Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for OTIC.

What is the current price target for Otonomy?

0 Wall Street analysts have set twelve-month price targets for Otonomy in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 189.9%.
View the latest price targets for OTIC.

What is the current consensus analyst rating for Otonomy?

Otonomy currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OTIC will outperform the market and that investors should add to their positions of Otonomy.
View the latest ratings for OTIC.

How do I contact Otonomy's investor relations team?

Otonomy's physical mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is (619) 323-2200 and its investor relations email address is [email protected] The official website for Otonomy is www.otonomy.com. Learn More about contacing Otonomy investor relations.